Backs FY25 adjusted EBITDA view $150M-$200M.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Reports 656% Net Income Surge
- Emergent BioSolutions Stockholders Elect Directors at Meeting
- Emergent BioSolutions announces $65M agreement to provide Ontario with NARCAN
- EBS Upcoming Earnings Report: What to Expect?
- Emergent Biosolutions: Strategic Share Repurchase and Diversified Revenue Streams Signal Strong Buy Opportunity